Search the Newsreel

Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop

Sarepta Therapeutics (SRPT) shares rose 5% after its Q2 2026 earnings report, despite a significant revenue drop, due to the company reporting positive GAAP operating income and tightening its full-year guidance. Investors see this as confirmation of the company's path to profitability, transitioning from …

Samsara CEO Sanjit Biswas sells $10.1m in company stock

Samsara Inc. CEO Sanjit Biswas sold over $10.1 million in Class A Common Stock in early August 2026 through pre-arranged Rule 10b5-1 trading plans. These sales involved shares held indirectly by the Biswas Family Trust and two other trusts, totaling 262,900 shares. The transactions …

Samsara Inc. (NYSE: IOT) CEO trusts sell 263,900 shares under 10b5-1 plans

Samsara Inc. CEO Sanjit Biswas's family trusts indirectly sold 263,900 shares of Class A Common Stock between August 4–6, 2026, at weighted-average prices ranging from $37.6120 to $39.3670 per share. These sales were conducted under pre-arranged Rule 10b5-1 trading plans established on September 29, …

Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT

Empowered Funds LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 1,898,816.7% in Q1, holding 113,935 shares valued at $2.48 million. Other institutional investors also adjusted their positions, and collective institutional ownership stands at 86.68%. Despite the company beating Q2 earnings and revenue …

Transcript : PENN Entertainment, Inc., Q2 2026 Earnings Call, Aug 06, 2026

This article provides the transcript of PENN Entertainment, Inc.'s Q2 2026 Earnings Call held on August 6, 2026. It highlights that PENN Entertainment's shares rose after beating Q2 earnings estimates, with reported adjusted EPS of $0.44 per share against an estimated $0.29, and revenue …

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

Sarepta Therapeutics (SRPT) is seeing a new strategic focus under its recently appointed CEO, with m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted earnings and total revenues that beat analyst estimates, despite a significant year-over-year decline in both figures, primarily due to lower Elevidys sales. The company updated its 2026 net product revenue guidance and raised its collaboration and other …

Sarepta’s new CEO Michael Severino faces critical milestones to prove growth

Sarepta Therapeutics' new CEO, Michael Severino, is navigating critical upcoming milestones that will determine the company's growth trajectory, including regulatory decisions for its Duchenne muscular dystrophy gene therapy Elevidys and exon-skipping treatments. Elevidys sales saw a sequential drop, though patient enrollment forms are increasing, …

Caesarstone Ltd (CSTE) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Caesarstone Ltd (CSTE), noting that no earnings forecast score is currently available, but the industry average is 7.25. Analysts predict a price target of $4.00 for CSTE, with an expected revenue of $105.20 million for the next …

Caesarstone Q2 Earnings Call Highlights

Caesarstone (CSTE) reported improved profitability in Q2 2026 despite lower revenue, with gross margin reaching 24% due to manufacturing restructuring and cost reductions. The company posted an adjusted EBITDA loss of $1 million, a significant improvement from the previous year. North American demand remained …

Sarepta Narrows 2026 Revenue Guidance on Elevidys Q2 Sales Dip

Sarepta Therapeutics reported a 34 percent decline in Q2 2026 revenue, primarily due to lower sales of its Duchenne muscular dystrophy gene therapy, Elevidys, following an FDA label narrowing last year. Despite this, the company beat Wall Street's revenue and EPS estimates. Sarepta has …

LENSAR sets robotic cataract laser webcast for Aug. 13

LENSAR (Nasdaq: LNSR) will release its second quarter 2026 financial results before the market opens on Thursday, August 13, 2026. The company will also host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results, recent developments, and …

CMRY's first-half net profit rises 17.88% to IDR 1.17 trillion

PENN Entertainment, Inc. Reports Second Quarter Results

PENN Entertainment, Inc. reported strong second-quarter 2026 financial results, achieving significant year-over-year growth in revenues and Adjusted EBITDA, driven by record Retail segment performance and continued improvement in its Interactive segment. The company highlighted successful execution of strategic priorities including deleveraging the balance sheet …

Royal Bank of Canada Reduces Position in Caesars Entertainment, Inc. $CZR

Royal Bank of Canada has reduced its stake in Caesars Entertainment, Inc. by 13.6% in the first quarter of 2026, selling 143,618 shares and retaining 915,440 shares valued at approximately $24.2 million. Institutional investors and hedge funds collectively own 91.79% of CZR. The stock …

LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026

LENSAR, Inc. announced it will release its second quarter 2026 financial results before market open on Thursday, August 13, 2026. Management will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results, recent corporate highlights, and …

Sarepta Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SRPT) 2026-08-06

Sarepta Therapeutics reported strong financial performance in Q2 2026, with GAAP operating income of $13 million and non-GAAP operating income of $86 million, and cash and investments growing to $945 million. The company narrowed its 2026 net product revenue guidance to $1.2 billion-$1.3 billion …

Samsara Inc. (IOT) Registers a Bigger Fall Than the Market: Important Facts to Note

Rossari Biotech withdraws from Nirmal Bang investor meet on Aug 10

Sarla Performance Fibers Q1 Results: Auditors issue qualified opinion

Samsara CFO Dominic Phillips sells USD 1.12 million in Class A shares

Samsara CFO Dominic Phillips sold 29,618 Class A common shares on August 3, with sales ranging from $37.58 to $38.4 per share, totaling approximately $1.12 million. Following the transaction, Phillips directly holds 836,100 shares, while the Phillips Family Trust indirectly holds 1,048,982 shares. This …

Sarepta forecasts $1.2B-$1.3B 2026 net product revenue as Cohort 8 12-week data shifts to Q1 2027

Earnings Call Insights: Sarepta Therapeutics (SRPT) Q2 2026 MANAGEMENT VIEW * “This is my first earnings call as CEO of Sarepta...” and “we have narrowed 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with a mid-point being the appropriate reference,” …

Sarla Performance Fibers consolidated net profit rises 67.22% in the June 2026 quarter

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Evolution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Caesarstone (NASDAQ:CSTE) Jumps as Q2 Loss Narrows Even as Revenue Misses

Caesarstone (NASDAQ:CSTE) saw its stock jump after reporting a narrower-than-expected adjusted Q2 loss, despite revenue missing consensus estimates. The company showed progress in margin improvement and cost restructuring, but North American demand remains weak and a new tariff threat on quartz surface products looms. …

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics (SRPT) reported $401.25 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 34.3%. EPS of $0.64 for the same period compares to $2.02 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $355.55 …

Informe de resultados de Sarepta: supera las estimaciones del segundo trimestre de 2026 y sus acciones suben en el mercado fuera de horario

Sarepta Therapeutics Q2 2026 Earnings Call Transcript

Sarepta Therapeutics reported strong financial performance in Q2 2026, with GAAP operating income of $13 million and non-GAAP operating income of $86 million, and cash and investments growing to $945 million. The company narrowed its 2026 net product revenue guidance to $1.2 billion-$1.3 billion …

Samsara Inc. (IOT) CFO sells 29,618 shares under Rule 10b5-1 plan

Samsara Inc.'s Executive Vice President and CFO, Dominic Phillips, reported the sale of 29,618 shares of Class A Common Stock on August 3, 2026. These sales were executed in four separate transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025. …

(LNSR) Volatility Zones as Tactical Triggers

This article analyzes Lensar Inc. (NASDAQ: LNSR), highlighting strong near-term sentiment amidst persistent mid and long-term weakness. It identifies a 96.5:1 risk-reward setup targeting a 37.0% gain with minimal risk, and provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging with …

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 …

Zensar Technologies Q1 Results: Earnings call transcript released

Earnings call transcript: Caesarstone beats Q2 2026 EPS forecast as revenue misses

Caesarstone (CSTE) reported a narrower-than-expected loss in Q2 2026 with adjusted diluted earnings of $0.10 per share, significantly beating analysts' forecast for a $0.26 loss. However, revenue missed expectations, coming in at $96.6 million against an anticipated $102.5 million, due to soft demand, particularly …

VICI and Caesars Join for NBA Arena Proposal

VICI Properties and Caesars Entertainment are collaborating on a proposal to construct a new NBA arena in Las Vegas. The arena would be located behind the Paris, Horseshoe, and Planet Hollywood hotel-casinos, utilizing approximately 50 acres of land owned by VICI and Caesars. This …

Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market

Sarepta Therapeutics is facing an FDA clinical hold on its Duchenne muscular dystrophy (DMD) therapy, Elevidys, due to safety concerns over acute liver failure, even as the global DMD market is projected to reach US$62.13 billion by 2030. Despite the hold, Sarepta has five …

Caesarstone Stock Rallies Despite Q2 2026 Loss Widens

Caesarstone Ltd. (NASDAQ:CSTE) reported a Q2 2026 adjusted loss per share of $0.10, which was significantly narrower than the anticipated $0.27 loss, leading to a positive stock reaction. Despite a 4.5% decline in revenue year-over-year, the company's cost discipline was highlighted as the main …